- Ipsen CEO David Loew said discussions are ongoing about building a US production site, with no decision yet on timing. The plant would manufacture either Dysport, the company’s Botox rival and second-largest drug by sales, or corabotase, a next-generation neurotoxin still in development.
- The move would mark Ipsen’s return to US manufacturing. The company previously had sites in Cambridge, Massachusetts, but currently owns no US plant and relies on external manufacturers there. Dysport is made at Wrexham in the UK, with additional sites in Dublin and the French towns of Dreux and Signes.
- Ipsen joins a broad onshoring wave driven by Trump administration tariff threats. AstraZeneca, Roche, Belgium’s UCB and Australia’s CSL have all announced US facility plans. Notably, Ipsen’s UK exports already enjoy a pharmaceutical tariff exemption under a US-UK agreement — and it is weighing a US plant regardless.
- A late-stage trial showed Dysport works in both episodic and chronic migraine, which Loew says would make Ipsen the first company with a neurotoxin covering both. Launch is targeted for the second half of 2027 pending approval, and the company has 2 billion euros ($2.32 billion) left for deals after acquiring Memo Therapeutics and Kartos Therapeutics in the past two months.
What Happened?
Ipsen confirmed it is evaluating a US manufacturing investment, without committing to a timeline. The company is separately spending 130 million euros ($150.9 million) expanding capacity at Wrexham, which a spokeswoman said does not preclude a US build. Loew framed the migraine data as a platform: with Dysport as an anchor product, Ipsen intends to pursue complementary late-stage deals to build a franchise around it. The broader strategy has been to diversify ahead of generic competition for Somatuline, its best-selling cancer drug.
Why It Matters?
The tariff exemption detail is the revealing one. Ipsen’s UK-made Dysport already ships into the US duty-free, so a US plant is not a narrow tariff workaround — it suggests European management now treats US production as a structural requirement rather than a response to a specific policy. That is a more durable shift than headline onshoring pledges imply, and it is showing up in mid-cap names, not just the AstraZenecas and Roches. The migraine indication is the other thing worth sizing. Chronic migraine is already a Botox stronghold for AbbVie; episodic migraine is a materially larger addressable population that no neurotoxin currently serves. If the label holds, Ipsen would be competing in an adjacent market rather than taking share in an established one.
What’s Next?
A site decision and its scope are the immediate items to watch, along with which product it is built for — corabotase would signal more confidence in the next-generation pipeline than a Dysport line would. Regulatory approval for the migraine indication is the 2027 catalyst, and the second-half launch target leaves little slack. With 2 billion euros of dry powder and a stated appetite for deals across clinical stages and therapeutic areas, further acquisitions are likely near term. The Somatuline generic erosion remains the offsetting pressure that this whole diversification effort is designed to absorb.
Source: The Wall Street Journal
